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INTRODUCTION 80 81 Acute rheumatic fever (ARF) results from an autoimmune response to infections 82 due to group A Streptococcus (GAS), Streptococcus pyogenes. Recurrences of ARF 83 and its associated cardiac valvular inflammation lead to chronic valvular damage 84 and rheumatic heart disease (RHD). RHD causes an estimated 275,000 deaths 85 annually with an estimated 33 million prevalent cases globally (reviewed [1] ). In 86 Australia, RHD is most prevalent in the Indigenous population, affecting 2-6 per 87 1000 individuals (and as high as 15/1000 school aged children in the northern 88 tropical regions [2] ) [3, 4] . 89
90
The precise pathological mechanisms underlying RHD remain unclear. One 91 hypothesis to explain inflammation of valvular tissue is molecular mimicry 92 (reviewed [1, [5] [6] [7] [8] ). Accordingly, peptides from GAS proteins are processed by 93 antigen presenting cells in the throat and heart tissue and presented on Human 94
Leukocyte Antigen (HLA) class II molecules to CD4+ T lymphocytes that elicit 95 pro-inflammatory cytokine responses and/or provide help to B lymphocytes for 96 antibody secretion. In RHD patients, the CD4 T cell epitopes and antigenic 97 specificities of antibodies show cross-reactivity to proteins in heart tissue, 98 specifically targeting cardiac valves [5, 9] . This cross-reactivity is thought to be 99 due to sequence similarities between heart tissues and GAS proteins, amongst 100 which GAS M-proteins feature prominently [10] , which is supported by studies of 101 HLA-DQ-restricted T cell clones that recognise the M protein and myosin 102 peptides in the blood and hearts of RHD patients [11, 12] as well as studies in 103 animal models of disease [13] . The precise mechanism by which these cross-4 reactive antibodies target the valve is unclear, and cross-reactive antibodies 105 have been observed in streptococcal pharyngitis without complications [14] . An 106 alternative hypothesis (reviewed [7] ) is that a streptococcal M protein N-107 terminus domain binds to the CB3 region in collagen type IV, initiating an 108 antibody response to the collagen which results in inflammation. These 109 antibodies do not cross-react with M proteins, and hence do not involve 110 molecular mimicry. 111 112 Key aspects of molecular mimicry are the relevant proteins/peptides in GAS 113 strains and host susceptibility. In the Northern Territory of Australia there is 114 high genetic diversity amongst GAS strains which reflect global-scale 115 transmission rather than localised diversification [15, 16] . Despite ubiquitous 116 exposure to GAS, only 1-2% of Indigenous Australians living in this region 117 develop RHD, and the cumulative incidence of ARF only reaches 5-6% in 118 communities with the most complete case ascertainment [17] . ARF is a 119 precursor to RHD, and in a meta-analysis of 435 twin pairs susceptibility to 120 rheumatic fever was estimated to be 60% heritable [18] . For RHD, a number of 121 candidate gene studies have variably reported associations with genes 122 controlling innate and adaptive immune responses (reviewed [6] ). Among these 123 candidates, HLA Class I and II genes feature most prominently, but with little 124 consistency in risk and protective genes/alleles reported [6, 19, 20] . Recently, a 125 GWAS of RHD was performed in Oceania populations but did not report an HLA 126 signal [21] . This variability in reported associations likely reflects differing study 127 designs, population-related genetic heterogeneity, failure to control for 128 confounding factors, and the vagaries of small samples sizes and candidate gene 129 5 approaches. Here we undertake an unbiased genome-wide approach to identify 130 genetic risk factors for RHD in echocardiogram-confirmed cases from the 131 Northern Territory of Australia. The HLA-DQA1-DQB1 locus was the only region 132 to show strong association in this population. We show that differential binding 133 of GAS/human cross-reactive epitopes to MHC Class II dimers for specific HLA 134 DQA1_DQB1 risk and protective haplotypes may underpin the molecular 135 mimicry hypothesis for RHD pathogenesis. where participants selected which components of the study they were 153 comfortable to participate in, and were able to withdraw from the study at any 154 6 stage [22] . This included an option to accept or refuse continued use of their 155 genetic or clinical data in further studies. De-identified post QC (cf. below) 156 genotype data for individuals who consented to continued use of their data have 157 been lodged in the European Genome-phenome Archive (accession number 158 EGAS0000000000) with access controlled through a study-specific Data Access 159 Committee. 160 161 Participants were recruited from 19 communities in the Northern Territory of 162 Australia (Figure 1 ). Case participants were defined a priori as having had, at 163 some stage, echocardiographically confirmed evidence of RHD and/or ARF with 164 carditis. For each of the 19 communities, we obtained a list of individuals on the 165 Northern Territory Rheumatic Heart Disease register. These lists were further 166 screened for patients with a history of ARF and associated carditis (defined using 167 the 2015 revised Jones Criteria [23] ) or RHD confirmed on echocardiogram 168 (defined using the 2012 World Heart Federation criteria [24]). We aimed for a 169 1:2 ratio of cases to controls. Controls were selected from the same communities 170 (range 4-215 participants/community) to ensure similar likelihood of exposure 171 to GAS among cases and controls, and included a selection of family members as 172 well as unrelated community-based controls. Medical records of potential 173 control participants were checked to exclude a prior history of rheumatic fever. 174
We did not perform echocardiograms on control participants. Both cases and 175 controls had to be aged ≥18 years, to minimise the likelihood of enrolling 176 controls that might subsequently become cases (given that ARF is largely a 177 disease of school aged children and most RHD cases are diagnosed before the age 7 of 30 (Table S1) We assessed the functional role for the candidate causal HLA variants in silico 249 using NetMHCIIPan 3.1 [34] to map epitopes and their binding affinities to two 250 risk and one protective HLA-DQA1_HLA-DQB1 haplotypes across GAS proteins 251 known to contain human cross-reactive epitopes. A literature review of the GAS 252 proteins reported to show cross-reactivity with host tissue proteins was 253 10 undertaken (Table S2 ). Full-length amino acid sequences of all GAS proteins, 254 including M5 and M6 proteins, shown to have cross-reactive epitopes were 255 converted to a series of 20-mer sequences with a 1-mer sliding window and 256 assessed for binding to each significantly associated DQA1_DQB1 haplotype. 257
Cross-reactive epitopes from human proteins were mapped onto the epitope 258 binding maps of M5 and M6, as indicated. Binding affinities were compared 259 (GraphPad Prism 7.00: 1-way ANOVA with multiple comparisons and correction 260 for multiple testing) between haplotypes across the regions of peak epitope 261 binding where 20-mer epitopes shared common 9-mer core epitopes. There are two important ways in which association between HLA-DQ haplotypes 324 could impact on disease susceptibility and control programs: (i) in the 325 pathogenesis of disease, particularly in relation to an autoimmune mechanism 326 for RHD through GAS epitopes that cross-react with self; and (ii) in the ability of 327 13 high risk individuals to respond to proposed vaccine antigens. To address the 328 first, we initially assessed the binding affinities of epitopes across the M-proteins 329 M5 and M6 from rheumatogenic GAS strains to the alpha/beta heterodimers 330 specific to the observed risk versus protective HLA-DQA-HLA-DQB haplotypes. 331 Figure 6 shows the epitope binding affinities mapped for these haplotypes across 332 the full-length M5 and M6 proteins, together with annotation indicating the 333 positions along each protein where experimentally validated cross-reactive 334 epitopes have been identified (Table S2 ). Several epitope peaks that correspond 335
to key cross-reactive epitopes are shown to bind with higher affinity to the two 336 risk haplotypes compared to the protective haplotype ( Figure 6 ), notably in the B 337 repeat regions previously shown to contain key cross-reactive T cell epitopes 338 with human cardiac myosin (e.g. Cunningham et al., 1997 [10] ; see also Table  339 S2). The peak differences in binding affinities for 20-mer epitopes in these 340 regions of previously experimentally validated cross reactivity for the M5 (see 341 arrows, Figure 6A ) and M6 (see arrows, Figure 6B ) proteins were highly 342 significant (P<0.0001) between risk and protective haplotypes ( Figure 7 ). No 343 differences in epitope binding to risk versus protective haplotypes were 344 observed when we mapped epitopes across GAS M proteins (e.g. E pattern M4 345 and M49 types [35]) from non-RHD GAS strains ( Figure S3 ). Nor did we observe 346 regions of differential epitope binding affinities across other GAS proteins 347 (HSP70, STRP1; Figure S3 ) reported in the literature to contain epitopes cross 348 reactive with human proteins implicated in RHD pathogenesis (Table S2) . to the inconsistency in the HLA genes/alleles associated with risk versus 370 protective from RHD in prior studies [6, 19, 20] even though experimental 371 studies support HLA-DQ restriction of T cell clones involved in T cell mimicry in 372 RHD [11] . In contrast, our study benefitted from dense fine mapping across HLA, 373 allowing us to identify specific risk (HLA-DQA1*0101_DQB1*0503; HLA-374 DQA1*0103_DQB1*0601) versus protective (HLA-DQA1*0301_DQB1*0402) 375 haplotypes across the genes encoding alpha and beta chains of HLA-DQ. While 376 our conditional analysis suggested only a single HLA signal, we cannot discount 377 15 the possibility that other genes may contribute to genetic susceptibility to RHD 378 in this population. It is of specific interest, however, that our study did not find 379 evidence for replication for variants at the IGH locus recently shown to be 380 significantly associated with RHD in a GWAS of New Caledonian and Fijian 381 populations [21] . Differences in study design and phenotype classification may 382 have contributed, as could genetic heterogeneity between indigenous 383 populations which is known to occur for autoimmune and infectious diseases 384 [38] . It is reassuring, nevertheless, that both GWAS have found evidence 385 consistent with autoimmune genetic architecture. Ultimately, meta-analyses of 386 greater statistical power will be required to investigate population-specific 387 differences and detect additional RHD loci. 388
389
Our identification of risk versus protective haplotypes across HLA-DQA/DQB 390 provided an opportunity to revisit the molecular mimicry hypothesis in relation 391 to RHD pathogenesis. Dimers created from alpha and beta chains of HLA class II 392 molecules present epitopes processed from foreign proteins to CD4 T cells, the 393 preferred outcome of which would be to provide an immune response that will 394 protect against infection. In the context of autoimmune disease, self-epitopes are 395 presented and recognised as non-self, leading to detrimental immune pathology. 396
The molecular mimicry hypothesis proposes that GAS contains proteins with AA 397 sequences that mimic (or are cross-reactive with) human proteins, thus leading 398 the immune system to recognise them as auto-antigens that drive immune 399 pathology rather than (or in addition to) immunity against GAS itself. [1, 6] In the 400 case of HLA-DQ, variation in exons 2 of both alpha and beta chains encoded by 401 DQA and DQB, respectively, contribute to variation in shape and structure of the 402 epitope binding pocket [39] . This means that the specific alpha/beta dimers 403 encoded by DQA/DQB genes carried on the same haplotype will create binding 404 pockets that have different characteristics in terms of ability to bind and present 405 epitopes to CD4+ T cells. Using the current gold standard NetMHCIIPan 3.1[34, 406 40] predictive algorithm to map specific epitopes across GAS proteins allowed us 407 to identify significant differences in the ability of dimers created from risk versus 408 protective haplotypes to bind cross-reactive epitopes. In particular, cross-409 reactive epitopes from cardiac myosin, one of the key cardiac proteins thought to 410 contribute to the molecular mimicry hypothesis in RHD [1, 6, 10] , were predicted 411 to bind to dimers created from risk haplotypes but have no predicted binding to 412 dimers created from the protective haplotype. Thus we identify a potential 413 molecular mechanism to account for immune pathogenesis causing RHD in this 414 population. Although we carried out our epitope mapping studies on just two 415 M5 and M6 GAS strains most studied for the presence of human cross-reactive 416 epitopes, our results are relevant to all GAS strains carrying cross-reactive N-417 terminal or B repeats. Relevance to our study population is consistent with 418 global-scale transmission of GAS strains in this remote Aboriginal population 419 [15] . Of interest too is the observation that, whilst rare cases of dimers created 420 by trans association of alpha/beta chains encoded on opposite strands of the 421 chromosome have been observed to contribute to susceptibility to type 1 422 diabetes, the predominant observation is that dimers are formed by alpha/beta 423 chains encoded in cis [39]. This likely contributes to our ability to identify risk 424 versus protective haplotypes across the HLA DQA1-DQB1 region, since strong 425 linkage disequilibrium will keep particular combinations of DQA/DQB genes 426 together in cis. 427 428 More broadly, this study represents a rare example of a genome-wide 429 association study in a remote Indigenous population, yet one which shows that 430 such studies can be successfully undertaken and uncover insights which have the 431 potential to inform pathogenesis and vaccination strategy. 432
433
In conclusion, we here present results of the first GWAS undertaken for RHD 434 in an Aboriginal Australian population. We report strong evidence for a role for 435 HLA DQ/DB Class II molecules, and we link this to significant differences in 436 affinity of binding of cross-reactive epitopes from GAS M proteins to antigen 437 presenting heterodimers formed by risk versus protective DQ-DB haplotypes. 438
Further functional analysis of T cell responses to cross-reactive T cell epitopes, 439
as carried out in previous studies [11] , could now be targeted at these specific 440 DQ-DB heterodimers. Overall, our results provide new data on mechanisms that 441 may contribute to risk of RHD caused by GAS strains. 442 black lines indicate the regions of known experimentally determined human T cell 641 epitopes (see Table S2 ). The apricot and pale blue vertical bars indicate the positions 642 of C-repeat region peptides incorporated into the StreptinCor and J8-DT vaccines, 643 respectively. 644 645 Figure 7 . Mean binding affinities for GAS M protein epitopes cross-reactive with 646 human cardiac myosin. (A) The y-axis (as for Figure 6 ) shows mean plus SD for 647 predicted M5 and M6 GAS protein epitopes (NT and B repeat regions; as annotated 648 with arrows in Figure 6 Table S1 . Basic demographic details (by gender, age at collection) for the 396 681 cases and 867 controls that passed all QC and were used in the GWAS analysis. 682 683   Table S2 . Summary of experimentally confirmed published epitopes for (A) GAS 684 M proteins for which there is evidence of cross-reaction with human heart- Plots showing binding affinities for predicted epitopes of GAS M proteins recognised by HLA DQ-DB heterodimers. Epitope binding predictions were performed in NetMHCIIPan3.1. The y-axis shows the relative binding affinity (expressed as 1-log 50,000 of the nM binding affinity) for heterodimers formed from risk (red, brown) and protective (blue) DQ_DB haplotypes (see key); the x-axis indicates the amino acid sequence locations for mature proteins, also equivalent to the start position of overlapping 20mers (1-mer sliding window) in (A) the GAS M5 sequence and (B) the GAS M6 sequence. Horizontal dotted lines show different nM binding affinities. Negative binding affinity is indicated at >10,000 nM (i.e. below the red dotted line). Vertical arrows indicate the N-terminal or B-repeat cross-reactive epitopes used to compare binding affinities in Figure 7 . The linear positions of known cross-reactive epitopes with human cardiac myosin and/or human heart valve tissue are shown in green; black lines indicate the regions of known experimentally determined human T cell epitopes (see Table S2 ). The apricot and pale blue vertical bars indicate the positions of C-repeat region peptides incorporated into the J8-DT and StreptinCor vaccines, respectively. Figure 6 ) shows mean plus SD for predicted M5 and M6 GAS protein epitopes (NT and B repeat regions; as annotated with arrows in Figure 6 ) recognised by risk (red and brown bars) or protective (blue bar) DQ-DB heterodimers formed from DQA1_DQB1 haplotypes, as labelled. **** indicated P<0.0001. (B) Shows the 20-mer epitope at the peak of the differences for binding affinity of risk versus protective haplotypes, together with the predicted 9-mer cores for each haplotype. Figure S3 . Plots showing binding affinities for predicted epitopes of GAS M proteins recognised by HLA DQ-DB heterodimers. Epitope binding predictions were performed in NetMHCIIPan3.1. The y-axis shows the relative binding affinity (expressed as 1-log 50,000 of the nM binding affinity) for heterodimers formed from risk (red, brown) and protective (blue) DQ_DB haplotypes (see key); the x-axis indicates the amino acid sequence locations for mature proteins, also equivalent to the start position of overlapping 20mers (1-mer sliding window) in non-rheumatogenic GAS M4 (Accession number CAA33269) and M49 (Accession number AAA26868.1) sequences, GAS HSP70 (Accession number AAB39223.1) and GAS STRP1 (Accession number AAA26987.1) sequences. Horizontal lines indicate 500nM (upper) and 1000nM (lower) binding affinities. Table S1 . Basic demographic details (by gender, age at collection) for the 396 cases and 867 controls that passed all QC and were used in the GWAS analysis. Table S2 . Summary of experimentally confirmed published epitopes for (A) GAS M proteins for which there is evidence of cross-reaction with human heartrelated proteins. (B) GAS M proteins for which there is evidence of non-cross-reactive T-and B-epitopes, and (C) other GAS proteins with evidence of crossreactive epitopes. Note 1: Bold and grey highlights indicate the region of the peptide epitope(s) that matches the AA location for the M5 (Accession Number CAM31002.1) and M6 (Accession Number AAA26920.1) protein sequences used in our epitopes mapping studies. AA locations are for the mature protein sequence (i.e. after removal of the signal peptide). * Peptide name from the relevant publication; **NT=N terminal region; B= B repeat region; C = C repeat region.
Note 2: Many of these epitopes have been worked on in murine and rat 21 models of disease, as recently reviewed, 22 which are not all referenced in this table.
